scholarly journals Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

Oncotarget ◽  
2016 ◽  
Vol 7 (45) ◽  
pp. 72622-72633 ◽  
Author(s):  
Lorenza Rimassa ◽  
Giovanni Abbadessa ◽  
Nicola Personeni ◽  
Camillo Porta ◽  
Ivan Borbath ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Second Line ◽  
Circulating Biomarkers ◽  
Randomized Phase Ii

scholarly journals Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)

ESMO Open ◽  
2022 ◽  
Vol 7 (1) ◽  
pp. 100314
Author(s):  
M.M. Javle ◽  
D.-Y. Oh ◽  
M. Ikeda ◽  
W.-P. Yong ◽  
K. Hsu ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Second Line ◽  
Tract Cancer ◽  
Randomized Phase Ii

Randomized Phase II Study of PARP Inhibitor Veliparib with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2021 ◽  
pp. clincanres.1789.2021
Author(s):  
E. Gabriela Chiorean ◽  
Katherine A Guthrie ◽  
Philip A Philip ◽  
Elizabeth M. Swisher ◽  
Florencia Jalikis ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Parp Inhibitor ◽  
Metastatic Pancreatic Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Randomized Phase Ii

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

2010 ◽  
Vol 29 (5) ◽  
pp. 1038-1044 ◽  
Author(s):  
José María Viéitez ◽  
Manuel Valladares ◽  
Ignacio Peláez ◽  
Luis de Sande González ◽  
Jesús García-Foncillas ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Randomized Phase Ii ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document